middle.news
Dimerix Nets US$30M Upfront from Amicus for Kidney Drug DMX-200
8:27am on Tuesday 6th of May, 2025 AEST
•
Healthcare
Read Story
Dimerix Nets US$30M Upfront from Amicus for Kidney Drug DMX-200
8:27am on Tuesday 6th of May, 2025 AEST
Key Points
US$30 million upfront payment from Amicus Therapeutics
Potential milestone payments up to US$560 million plus tiered royalties
Fourth licensing deal for DMX-200 across multiple territories
Total potential payments from all licenses around AU$1.4 billion
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE